Explore our resources by research/diagnostic specialty or content type

ALPCO specialists are leveraging their extensive expertise to create a growing collection of resources for your research and testing. Find resources that benefit your work using the handy filters.

Blogs

Researching the Role of Gut Permeability in NAFLD
March 6, 2018

Researching the Role of Gut Permeability in NAFLD

[playlist images="false" artists="false" tracklist="false" ids="4600"] A growing amount of research demonstrates that communication between the gut microbiota and liver is vital for the regulation of energy metabolism1,2. As a result, scientists are further exploring the relationship between the gut microbiota and gut-liver crosstalk to better understand metabolic diseases such as non-alcoho...
Obesity Induced Adipose Tissue Dysfunction and NAFLD
February 20, 2018

Obesity Induced Adipose Tissue Dysfunction and NAFLD

Obesity is a known risk factor for developing metabolic diseases such as non-alcoholic fatty liver disease (NAFLD)1. An increasing amount of evidence shows that obesity induced adipose tissue dysfunction and NAFLD development are closely related2. Obesity induced changes to adipokine secretion can have detrimental effects on adiponectin and adipose tissue-liver crosstalk, leptin and inflammatio...
ALPCO and InSphero Collaborate to Advance Metabolic Disease Research at ADA 2017
June 6, 2017

ALPCO and InSphero Collaborate to Advance Metabolic Disease Research at ADA 2017

Date: June 6, 2017 ALPCO announced it will collaborate with InSphero, a supplier of 3D cell culture solutions, at the ADA’s 77th Scientific Sessions June 10-12 in San Diego. Together, ALPCO and InSphero aim to enhance the study of islet function, regeneration, and preservation by providing researchers with methods to perform 3D islet microtissue culture, as well as assays for measuring gluca...
 Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD to be Launched at Digestive Disease Week
May 2, 2017

New Zonulin ELISAs and Therapeutic Drug Monitoring Assays for IBD to be Launched at Digestive Disease Week®

We are excited to announce that we will launch new gastrointestinal and inflammatory bowel disease (IBD) assays at Digestive Disease Week® May 7-9, 2017 in Chicago, IL. Included in this release are the Zonulin Stool ELISA and Zonulin Serum ELISA to aid in the study of gut permeability and celiac disease. Both assays specifically quantify levels of zonulin with no cross-reactivity to haptoglobin...
Adiponectin in NAFLD and NASH Research
March 7, 2017

The Impact of Adiponectin in NAFLD and NASH Research

Date: March 7, 2017 Lately, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been widely discussed in both the clinical and research communities. Some of the focus has been related to alternative research methods that can improve diagnostic and monitoring methodologies at the clinical level. These include more sophisticated imaging techniques as well as n...
Emerging Biomarker Research in NAFLD and NASH
February 21, 2017

Emerging Biomarker Research in NAFLD and NASH

Nonalcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease in the western hemisphere affecting 1 in 3 adults and 1 in 10 children1.  Today, liver biopsies are the only gold standard for precise diagnosis of NAFLD2. Because of this, there are tremendous efforts on the research and clinical side to introduce newer, less invasive methodologies which will aid in diag...
Alternative NAFLD and NASH Screening Methods
January 24, 2017

[Infographic] Alternative NAFLD and NASH Screening Methods

Download our infographic to understand the prevalence of NAFLD and NASH, as well as how biomarkers can serve as alternative NAFLD and NASH screening methods.   Download Now Estimated Global Prevalence of NAFLD Research confirms that nonalcoholic fatty liver disease (NAFLD) has an estimated global prevalence of 25% and is now considered to be a global pandemic1,2. Trends in data...
Choosing the Relevant GLP-1 Species to Study
November 29, 2016

Choosing the Relevant GLP-1 Species to Study

  A better understanding of incretins has led to tremendous therapeutic advances in the field of type 2 diabetes1. These hormones are released from the gut in response to food ingestion and lead to the stimulation of pancreatic β-cells which then release insulin in a glucose-concentration dependent manner1. One such hormone is glucagon-like peptide-1 (GLP-1) that has been shown to initi...
Endocrine Disrupting Chemicals and Biomarkers of EDC
October 12, 2016

Endocrine Disrupting Chemicals and Biomarkers

Introduction Humans and the environment are exposed to numerous chemicals every day1. Each year, about 2,000 new chemicals are manufactured in the U.S.2. Research findings over the years have shown how some chemicals known as endocrine disrupting chemicals (EDCs) can interact with the endocrine system, disrupt homeostasis, and lead to issues such as obesity and sterility1. As a result, endocri...
Regulating Endocrine Disrupting Chemicals
September 27, 2016

Regulating Endocrine Disrupting Chemicals in Consumer Products

Date: September 27, 2016 Author: Andrea Tarbet, Product Marketing Associate at ALPCO From cosmetics to water bottles, endocrine disrupting chemicals (EDCs) have surfaced in our everyday lives. EDCs are compounds that can interfere with the endocrine system’s ability to help an organism develop, grow, reproduce, and maintain overall homeostasis1.  Since EDCs are found nearly everywhere, we...